presentation

(redirected from Antigen presentation)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to Antigen presentation: clonal expansion, antigen recognition
References in periodicals archive ?
In this present article, we demonstrate three important consequences of PRN exposure on the in vitro parameters of CTL activation and their functional activity as effectors of cell-mediated immunity: a) antigen presentation to CTLs is not impaired, b) the functional lytic activity of primary (1[degrees]) CTLs is only marginally impaired, and c) upon restimulation of 1[degrees] CTLs in the absence of PRN, the secondary (2[degrees]) CTL response is completely abrogated.
Our novel platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor.
The Company's peptide or nucleic acid-based immunotherapeutics comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems.
1 and LFA-3, to enhance antigen presentation and activation of immune responses critical for tumor destruction.
Our novel platform technology generates a more comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor.
In various aspects the invention provides nucleic acid, including coding sequences, oligonucleotide primers and probes, polypeptides, pharmaceutical compositions, methods of diagnosis or prognosis, and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases, such as glomerulonephritis, diseases and disorders involving disruption of endocytosis and/or antigen presentation, diseases and disorders involving cytokine clearance and/or inflammation, viral infection, elevation of free fatty acids or hypercholesterolemia, osteoporosis, Alzheimer's disease, and diabetes.
ImmunoVEX -- a Unique Dendritic Cell Based Vaccine Platform Considerable evidence from advanced clinical trials has shown that antigen presentation by the immune systems key policing cells -- dendritic cells -- can lead to a therapeutically effective immune response against disease associated antigens to which the body has become tolerant.
The technology uses the patient's own B cells for antigen production, as well as for antigen presentation.
These discoveries and subsequent research indicate that modulation of the CD1 antigen presentation pathway has significant therapeutic potential in a wide range of infectious diseases, in cancer, and in autoimmune diseases.
Some of the advantages include: 1) prolonged antigen presentation by B cells (5 days) as compared to the short presentation time by dendritic cells (12 hours); 2) a unique patented platform technology using a universal cancer antigen (marker) that is increased in approximately 85% of all tumors; 3) induces an immune response after a single injection; 4) no need for complicated culture procedures; 5) much fewer steps; and, 6) lower cost.
The Company's vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells and helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing).
Ligand Epitope Antigen Presentation System) is being presented as a therapy to arrest the progression of RA disease bodes well for those hoping that the technology's same anti-inflammatory properties and ability to direct an immune response against specific disease epitopes will produce strong evidence and a case for CEL-SCI's investigational LEAPS-H1N1 treatment.